<DOC>
	<DOCNO>NCT01045382</DOCNO>
	<brief_summary>The present project aim evaluate capacity MSC improve one-year overall survival patient transplant HLA-mismatched PBSC relate unrelated donor non-myeloablative conditioning . Co-infusion MSC show facilitate engraftment hematopoietic stem cell ( HSC ) immunodeficient mouse model . In addition , show infusion third party MSC HSC transplantation could successfully use treatment grade II-IV steroid-refractory acute graft versus host disease . One hundred twenty patient HLA-mismatched donor include 6 year multiple center across Belgium transplant committee Belgian Hematological Society . The condition regimen consist fludarabine 2 Gy TBI , follow infusion donor HSC . Patients randomize 1/1 double-blind fashion receive MSC ( 1.5-.3.0 x106/kg ) third-party ( either haploidentical family member unrelated volunteer ) donor day 0 . Postgrafting immunosuppression combine tacrolimus MMF . Except collection , expansion infusion MSC , clinical management patient differ routine NM-HCT .</brief_summary>
	<brief_title>MSC HSC Coinfusion Mismatched Minitransplants</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Theoretical indication standard allotransplant , feasible : Age &gt; 55 yr . Unacceptable end organ performance . Patient 's refusal . Indication standard autotransplant : perform miniallotransplantation 26 month standard autotransplant . Male female ; fertile female patient must use reliable contraception method Age â‰¤ 75 year old Informed consent give patient his/her guardian minor age . One two HLA mismatch PBSC : One antigenic mismatch HLAA B C DRB1 DQB1 Two allelic mismatch HLAA B C DRB1 DQB1 One antigenic mismatch : 1 allelic mismatch HLAA B C DRB1 DQB1 . One antigenic mismatch DQB1 one antigenic mismatch HLAA B C DRB1 Patients one single allelic mismatch HLAA B C DRB1 DQB1 also include protocol . Hematological malignancy confirm histologically rapidly progress : AML complete remission ALL complete remission CML unresponsive/intolerant Imatinib blast crisis Other myeloproliferative disorder blast crisis extensive myelofibrosis MDS &lt; 5 % blast Multiple myeloma rapidly progress CLL NonHodgkin 's lymphoma ( aggressive NHL chemosensitive ) Hodgkin 's disease Any condition fulfil inclusion criterion HIV positive Terminal organ failure , except renal failure ( dialysis acceptable ) Cardiac : Symptomatic coronary artery disease cardiac failure require therapy ; ejection fraction &lt; 35 % ; uncontrolled arrhythmia ; uncontrolled hypertension Pulmonary : DLCO &lt; 35 % and/or receive supplementary continuous oxygen Hepatic : Fulminant liver failure , cirrhosis liver evidence portal hypertension , alcoholic hepatitis , esophageal varix , history bleed esophageal varix , hepatic encephalopathy , uncorrectable hepatic synthetic dysfunction evince prolongation prothrombin time , ascites related portal hypertension , bacterial fungal liver abscess , biliary obstruction , chronic viral hepatitis total serum bilirubin &gt; 3 mg/dL , symptomatic biliary disease Uncontrolled infection , arrhythmia hypertension Previous radiation therapy precluding use 2 Gy TBI 10/10 HLAA , B , C , DRB1 DQBI allelematched donor fit to/willing donate PBSC .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>HSC transplantation</keyword>
	<keyword>HLA-mismatched</keyword>
	<keyword>Mesenchymal stem cell</keyword>
	<keyword>GVHD</keyword>
	<keyword>co-infusion</keyword>
</DOC>